Product Description
berberine is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism.
Mechanisms of Action: AMPK Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | China | Hong Kong | India | Korea | New Zealand | Russia | Taiwan | United Arab Emirates | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: HighTide Biopharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Armenia, China, Sweden
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Type 2 Diabetes
Phase 1: Gastroenteritis|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20244648 |
CTR20244648 | P1 |
Completed |
Gastroenteritis |
2025-03-02 |
2025-08-05 |
||
NCT06415773 |
HARMONY | P3 |
Completed |
Type 2 Diabetes |
2025-06-13 |
9% |
2025-11-18 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04918667 |
EP-1007 | P1 |
Not yet recruiting |
Healthy Volunteers |
2025-11-01 |
69% |
2023-09-15 |
|
CTR20234184 |
CTR20234184 | P1 |
Completed |
Healthy Volunteers |
2024-07-19 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06350890 |
SYMPHONY-1 | P3 |
Completed |
Type 2 Diabetes |
2024-12-12 |
7% |
2025-11-18 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT06353347 |
SYMPHONY-2 | P3 |
Completed |
Type 2 Diabetes |
2024-12-12 |
7% |
2025-11-18 |
Primary Completion Date|Primary Endpoints |